isoproterenol has been researched along with Becker Muscular Dystrophy in 10 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Electrocardiography on isoproterenol challenged mice showed that both models developed arrhythmias and died within 24 hours, while wild-type mice were free of pathology." | 7.81 | Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice. ( Contreras, JE; Fraidenraich, D; Gonzalez, JP; Ramachandran, J; Xie, LH, 2015) |
| " Electrocardiography on isoproterenol challenged mice showed that both models developed arrhythmias and died within 24 hours, while wild-type mice were free of pathology." | 3.81 | Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice. ( Contreras, JE; Fraidenraich, D; Gonzalez, JP; Ramachandran, J; Xie, LH, 2015) |
| "Patients with Duchenne muscular dystrophy (DMD) commonly present with severe ventricular arrhythmias that contribute to heart failure." | 1.51 | S-nitrosylation of connexin43 hemichannels elicits cardiac stress-induced arrhythmias in Duchenne muscular dystrophy mice. ( Contreras, JE; Fraidenraich, D; Himelman, E; Lillo, MA; Shirokova, N; Xie, LH, 2019) |
| "Duchenne muscular dystrophy is a fatal cardiac and skeletal muscle disease resulting from mutations in the dystrophin gene." | 1.42 | Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy-Associated Cardiomyopathy. ( Crosbie-Watson, RH; Jordan, MC; Marshall, JL; Nguyen, RT; Parvatiyar, MS; Richardson, VA; Roos, KP, 2015) |
| "Cardiomyopathy in Duchenne muscular dystrophy (DMD) is an increasing cause of death in patients." | 1.37 | Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. ( Guerron, AD; Hoffman, EP; Nagaraju, K; Sali, A; Spurney, CF; van der Meulen, JH; Yu, Q, 2011) |
| "Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death." | 1.37 | Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. ( Canan, BD; Chimanji, NS; Delfín, DA; Ganguly, R; Janssen, PM; Martin, CD; Mays, TA; Murray, JD; Rafael-Fortney, JA; Raman, SV; Schill, KE; Stangland, JE; Tran, T; Xu, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lillo, MA | 1 |
| Himelman, E | 1 |
| Shirokova, N | 1 |
| Xie, LH | 2 |
| Fraidenraich, D | 2 |
| Contreras, JE | 2 |
| Sullivan, RT | 1 |
| Lam, NT | 1 |
| Haberman, M | 1 |
| Beatka, MJ | 1 |
| Afzal, MZ | 1 |
| Lawlor, MW | 1 |
| Strande, JL | 1 |
| Caluori, G | 1 |
| Pribyl, J | 1 |
| Pesl, M | 1 |
| Jelinkova, S | 1 |
| Rotrekl, V | 1 |
| Skladal, P | 1 |
| Raiteri, R | 1 |
| Meyers, TA | 1 |
| Heitzman, JA | 1 |
| Krebsbach, AM | 1 |
| Aufdembrink, LM | 1 |
| Hughes, R | 1 |
| Bartolomucci, A | 1 |
| Townsend, D | 1 |
| Li, Y | 1 |
| Zhang, S | 1 |
| Zhang, X | 1 |
| Li, J | 1 |
| Ai, X | 1 |
| Zhang, L | 1 |
| Yu, D | 1 |
| Ge, S | 1 |
| Peng, Y | 1 |
| Chen, X | 1 |
| Gonzalez, JP | 1 |
| Ramachandran, J | 1 |
| Parvatiyar, MS | 1 |
| Marshall, JL | 1 |
| Nguyen, RT | 1 |
| Jordan, MC | 1 |
| Richardson, VA | 1 |
| Roos, KP | 1 |
| Crosbie-Watson, RH | 1 |
| Spurney, CF | 1 |
| Guerron, AD | 1 |
| Yu, Q | 1 |
| Sali, A | 1 |
| van der Meulen, JH | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Rafael-Fortney, JA | 1 |
| Chimanji, NS | 1 |
| Schill, KE | 1 |
| Martin, CD | 1 |
| Murray, JD | 1 |
| Ganguly, R | 1 |
| Stangland, JE | 1 |
| Tran, T | 1 |
| Xu, Y | 1 |
| Canan, BD | 1 |
| Mays, TA | 1 |
| Delfín, DA | 1 |
| Janssen, PM | 1 |
| Raman, SV | 1 |
| Yue, Y | 1 |
| Skimming, JW | 1 |
| Liu, M | 1 |
| Strawn, T | 1 |
| Duan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
10 other studies available for isoproterenol and Becker Muscular Dystrophy
| Article | Year |
|---|---|
S-nitrosylation of connexin43 hemichannels elicits cardiac stress-induced arrhythmias in Duchenne muscular dystrophy mice.
Topics: Adrenergic beta-Agonists; Animals; Arrhythmias, Cardiac; Cell Membrane; Cell Membrane Permeability; | 2019 |
Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Female; Fibrosis; Isoproterenol; Mice, Inbred mdx | 2021 |
Non-invasive electromechanical cell-based biosensors for improved investigation of 3D cardiac models.
Topics: Biosensing Techniques; Cell Differentiation; Dystrophin; Fibroblasts; Humans; Induced Pluripotent St | 2019 |
Acute AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathies; Dystrophin; Heart; Humans; Isopr | 2019 |
Blunted cardiac beta-adrenergic response as an early indication of cardiac dysfunction in Duchenne muscular dystrophy.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Calcium; Calcium Channels, L-Type; Calcium-Binding P | 2014 |
Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Connexin 43; Disease Models, Animal; Female; Humans; Isop | 2015 |
Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy-Associated Cardiomyopathy.
Topics: Animals; Cardiomyopathies; Carrier Proteins; Creatine Kinase, MB Form; Echocardiography; Fluorescent | 2015 |
Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
Topics: Adrenergic beta-Agonists; Analysis of Variance; Animals; Aortic Valve; Blood Pressure; Body Weight; | 2011 |
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
Topics: Animals; Cardiac Imaging Techniques; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; D | 2011 |
Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Dystrophin; Female; Genetic Therapy; Heterozygote; Is | 2004 |